These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36647005)

  • 1. Experimental analysis of bladder cancer-associated mutations in EP300 identifies EP300-R1627W as a driver mutation.
    Luo M; Zhang Y; Xu Z; Lv S; Wei Q; Dang Q
    Mol Med; 2023 Jan; 29(1):7. PubMed ID: 36647005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients.
    Zhu G; Pei L; Li Y; Gou X
    Aging (Albany NY); 2020 Feb; 12(3):2132-2141. PubMed ID: 32012118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
    Ring A; Kaur P; Lang JE
    BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder.
    Boorjian SA; Heemers HV; Frank I; Farmer SA; Schmidt LJ; Sebo TJ; Tindall DJ
    Endocr Relat Cancer; 2009 Mar; 16(1):123-37. PubMed ID: 18845648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frameshift mutations of tumor suppressor gene EP300 in gastric and colorectal cancers with high microsatellite instability.
    Kim MS; Lee SH; Yoo NJ; Lee SH
    Hum Pathol; 2013 Oct; 44(10):2064-70. PubMed ID: 23759652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional Impact of Chromatin Remodeling Gene Mutations and Predictive Signature for Therapeutic Response in Bladder Cancer.
    Duex JE; Swain KE; Dancik GM; Paucek RD; Owens C; Churchill MEA; Theodorescu D
    Mol Cancer Res; 2018 Jan; 16(1):69-77. PubMed ID: 28970362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder.
    Gui Y; Guo G; Huang Y; Hu X; Tang A; Gao S; Wu R; Chen C; Li X; Zhou L; He M; Li Z; Sun X; Jia W; Chen J; Yang S; Zhou F; Zhao X; Wan S; Ye R; Liang C; Liu Z; Huang P; Liu C; Jiang H; Wang Y; Zheng H; Sun L; Liu X; Jiang Z; Feng D; Chen J; Wu S; Zou J; Zhang Z; Yang R; Zhao J; Xu C; Yin W; Guan Z; Ye J; Zhang H; Li J; Kristiansen K; Nickerson ML; Theodorescu D; Li Y; Zhang X; Li S; Wang J; Yang H; Wang J; Cai Z
    Nat Genet; 2011 Aug; 43(9):875-8. PubMed ID: 21822268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression.
    Ogiwara H; Sasaki M; Mitachi T; Oike T; Higuchi S; Tominaga Y; Kohno T
    Cancer Discov; 2016 Apr; 6(4):430-45. PubMed ID: 26603525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico analysis reveals EP300 as a panCancer inhibitor of anti-tumor immune response via metabolic modulation.
    Krupar R; Watermann C; Idel C; Ribbat-Idel J; Offermann A; Pasternack H; Kirfel J; Sikora AG; Perner S
    Sci Rep; 2020 Jun; 10(1):9389. PubMed ID: 32523042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EP300 as a Molecular Integrator of Fibrotic Transcriptional Programs.
    Rubio K; Molina-Herrera A; Pérez-González A; Hernández-Galdámez HV; Piña-Vázquez C; Araujo-Ramos T; Singh I
    Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of MIR9‑3HG inhibits proliferation and promotes apoptosis of cervical cancer cells by miR‑498 via EP300.
    Li F; Liang Y; Ying P
    Mol Med Rep; 2021 Nov; 24(5):. PubMed ID: 34468010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and Prognostic Significance of
    Godlewski J; Krazinski BE; Kowalczyk AE; Kiewisz J; Kiezun J; Kwiatkowski P; Sliwińska-Jewsiewicka A; Wierzbicki PW; Kmieć Z
    Anticancer Res; 2017 Jun; 37(6):2927-2937. PubMed ID: 28551630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis.
    Huang YH; Cai K; Xu PP; Wang L; Huang CX; Fang Y; Cheng S; Sun XJ; Liu F; Huang JY; Ji MM; Zhao WL
    Signal Transduct Target Ther; 2021 Jan; 6(1):10. PubMed ID: 33431788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic EP300-G211S mutations are associated with overall somatic mutational patterns and breast cancer specific survival in triple-negative breast cancer.
    Bemanian V; Noone JC; Sauer T; Touma J; Vetvik K; Søderberg-Naucler C; Lindstrøm JC; Bukholm IR; Kristensen VN; Geisler J
    Breast Cancer Res Treat; 2018 Nov; 172(2):339-351. PubMed ID: 30132219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers.
    Sarkar S; Jülicher KP; Burger MS; Della Valle V; Larsen CJ; Yeager TR; Grossman TB; Nickells RW; Protzel C; Jarrard DF; Reznikoff CA
    Cancer Res; 2000 Jul; 60(14):3862-71. PubMed ID: 10919661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP.
    Qian M; Zhang H; Kham SK; Liu S; Jiang C; Zhao X; Lu Y; Goodings C; Lin TN; Zhang R; Moriyama T; Yin Z; Li Z; Quah TC; Ariffin H; Tan AM; Shen S; Bhojwani D; Hu S; Chen S; Zheng H; Pui CH; Yeoh AE; Yang JJ
    Genome Res; 2017 Feb; 27(2):185-195. PubMed ID: 27903646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.
    Asaduzzaman M; Constantinou S; Min H; Gallon J; Lin ML; Singh P; Raguz S; Ali S; Shousha S; Coombes RC; Lam EW; Hu Y; Yagüe E
    Breast Cancer Res Treat; 2017 Jun; 163(3):461-474. PubMed ID: 28341962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of somatic mutations in the catalytic domains of CREBBP and EP300 genes implies a role for histone deacetylase inhibition in myeloproliferative neoplasms.
    Andersen CL; Hasselbalch H; Grønbæk K
    Leuk Res; 2012 Apr; 36(4):485-7. PubMed ID: 22177454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies.
    Scialdone A; Khazaei S; Hasni MS; Lennartsson A; Gullberg U; Drott K
    Exp Hematol; 2019 Nov; 79():35-46.e1. PubMed ID: 31669559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importin-11 overexpression promotes the migration, invasion, and progression of bladder cancer associated with the deregulation of CDKN1A and THBS1.
    Zhao J; Shi L; Zeng S; Ma C; Xu W; Zhang Z; Liu Q; Zhang P; Sun Y; Xu C
    Urol Oncol; 2018 Jun; 36(6):311.e1-311.e13. PubMed ID: 29602637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.